← Back to Clinical Trials
Recruiting NCT05387369
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
Trial Parameters
Condition COVID-19
Sponsor Huashan Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 2,000
Sex ALL
Min Age 12 Years
Max Age N/A
Start Date 2022-03-21
Completion 2023-03-30
Interventions
Paxlovid
Brief Summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Eligibility Criteria
Inclusion Criteria: * Participants who have a positive SARS-CoV-2 test result; * Participants who have one or more mild or moderate COVID-19 symptoms. Exclusion Criteria: * No specific exclusion criteria in this real world study.
Related Trials
NCT06300853
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination St
View Trial →
NCT06006884
A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
View Trial →
NCT05848427
The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Pa
View Trial →